← AMN Healthcare Services overview

AMN Healthcare Services vs NeoGenomics: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

AMN Healthcare Services Inc (AMN)

Q3 2026
▲3▼1

AMN's staffing rebound and AI push drive profit swing, but two units still shrink

  • AI workforce intelligence partnership AMN and Brightfield launched a first-of-its-kind partnership that adds outside market data to AMN's AI-powered workforce tools. This makes AMN's services more valuable to hospitals, supporting demand and pricing power, and reinforces its technology leadership.

    New partnership expands AMN's AI-driven offerings, a key growth driver.

  • Travel nurse and allied volume growth accelerates Travel nurse volume grew 6% and allied volume 7% in Q2, the strongest in four years, with guidance for over 10% growth in both for Q3. This signals a real rebound in demand for AMN's core staffing services, pushing revenue and profit higher.

    Core staffing demand rebound is the main force behind AMN's improving results.

  • Q2 profit swing and raised guidance AMN swung to a $21.2 million profit and adjusted EPS of $0.77, more than double last year, with revenue beating guidance. Management now expects strong Q3 volume growth, boosting investor confidence and the stock's valuation.

    Profit swing and upbeat guidance directly lift earnings expectations and stock price.

  • Physician and tech segments keep shrinking Physician and Leadership Solutions revenue fell 6% and Technology and Workforce Solutions dropped 15%, with further declines expected in Q3. These weak spots drag on overall growth and show AMN's recovery is uneven, a real counterweight to the good news.

    Ongoing weakness in two segments offsets the staffing rebound and tempers the bullish story.

August 2026
▲3▼1

AMN's staffing rebound and AI push drive profit swing, but two units still shrink

  • AI workforce intelligence partnership AMN and Brightfield launched a first-of-its-kind partnership that adds outside market data to AMN's AI-powered workforce tools. This makes AMN's services more valuable to hospitals, supporting demand and pricing power, and reinforces its technology leadership.

    New partnership expands AMN's AI-driven offerings, a key growth driver.

  • Travel nurse and allied volume growth accelerates Travel nurse volume grew 6% and allied volume 7% in Q2, the strongest in four years, with guidance for over 10% growth in both for Q3. This signals a real rebound in demand for AMN's core staffing services, pushing revenue and profit higher.

    Core staffing demand rebound is the main force behind AMN's improving results.

  • Q2 profit swing and raised guidance AMN swung to a $21.2 million profit and adjusted EPS of $0.77, more than double last year, with revenue beating guidance. Management now expects strong Q3 volume growth, boosting investor confidence and the stock's valuation.

    Profit swing and upbeat guidance directly lift earnings expectations and stock price.

  • Physician and tech segments keep shrinking Physician and Leadership Solutions revenue fell 6% and Technology and Workforce Solutions dropped 15%, with further declines expected in Q3. These weak spots drag on overall growth and show AMN's recovery is uneven, a real counterweight to the good news.

    Ongoing weakness in two segments offsets the staffing rebound and tempers the bullish story.

Latest
▲3▼1

AMN's staffing rebound and AI push drive profit swing, but two units still shrink

  • AI workforce intelligence partnership AMN and Brightfield launched a first-of-its-kind partnership that adds outside market data to AMN's AI-powered workforce tools. This makes AMN's services more valuable to hospitals, supporting demand and pricing power, and reinforces its technology leadership.

    New partnership expands AMN's AI-driven offerings, a key growth driver.

  • Travel nurse and allied volume growth accelerates Travel nurse volume grew 6% and allied volume 7% in Q2, the strongest in four years, with guidance for over 10% growth in both for Q3. This signals a real rebound in demand for AMN's core staffing services, pushing revenue and profit higher.

    Core staffing demand rebound is the main force behind AMN's improving results.

  • Q2 profit swing and raised guidance AMN swung to a $21.2 million profit and adjusted EPS of $0.77, more than double last year, with revenue beating guidance. Management now expects strong Q3 volume growth, boosting investor confidence and the stock's valuation.

    Profit swing and upbeat guidance directly lift earnings expectations and stock price.

  • Physician and tech segments keep shrinking Physician and Leadership Solutions revenue fell 6% and Technology and Workforce Solutions dropped 15%, with further declines expected in Q3. These weak spots drag on overall growth and show AMN's recovery is uneven, a real counterweight to the good news.

    Ongoing weakness in two segments offsets the staffing rebound and tempers the bullish story.

NeoGenomics Inc (NEO)

Q3 2026
▲4

NeoGenomics rides new FDA test, raised guidance, and CEO transition

  • FDA-approved prostate cancer test launch NeoGenomics launched PTEN IHC CDx, the first FDA-approved lab test to identify prostate cancer patients eligible for AstraZeneca's targeted therapy TRUQAP. This new product expands its oncology menu and could drive future testing demand, pushing the stock up 3.4% on the news.

    New product launch is a fresh growth driver that directly boosts revenue potential.

  • Raised 2026 revenue and profit guidance After strong Q2 results, NeoGenomics raised its full-year 2026 revenue outlook to $802–$806 million and lifted adjusted EBITDA guidance to $56–$58 million. Clinical revenue grew 14%, led by a 26% jump in next-generation sequencing, showing the core business is accelerating.

    Guidance raise signals stronger-than-expected business momentum, a key positive for the stock.

  • Preliminary Q3 revenue beats consensus NeoGenomics reported preliminary third-quarter revenue of about $209 million, topping the $205.9 million consensus estimate, with very strong next-generation sequencing growth. The company also plans to raise its full-year guidance, reinforcing confidence in its growth trajectory.

    Better-than-expected quarterly revenue and a guidance hike are fresh positive catalysts.

  • CEO succession and board refresh Warren Stone, current President and COO, will become CEO in January 2027, with current CEO Tony Zook moving to Executive Chair. The planned transition and board expansion aim to support the next phase of growth, which investors took as a positive signal.

    Leadership change is a new event that can affect investor confidence and future strategy.

August 2026
▲4

NeoGenomics rides new FDA test, raised guidance, and CEO transition

  • FDA-approved prostate cancer test launch NeoGenomics launched PTEN IHC CDx, the first FDA-approved lab test to identify prostate cancer patients eligible for AstraZeneca's targeted therapy TRUQAP. This new product expands its oncology menu and could drive future testing demand, pushing the stock up 3.4% on the news.

    New product launch is a fresh growth driver that directly boosts revenue potential.

  • Raised 2026 revenue and profit guidance After strong Q2 results, NeoGenomics raised its full-year 2026 revenue outlook to $802–$806 million and lifted adjusted EBITDA guidance to $56–$58 million. Clinical revenue grew 14%, led by a 26% jump in next-generation sequencing, showing the core business is accelerating.

    Guidance raise signals stronger-than-expected business momentum, a key positive for the stock.

  • Preliminary Q3 revenue beats consensus NeoGenomics reported preliminary third-quarter revenue of about $209 million, topping the $205.9 million consensus estimate, with very strong next-generation sequencing growth. The company also plans to raise its full-year guidance, reinforcing confidence in its growth trajectory.

    Better-than-expected quarterly revenue and a guidance hike are fresh positive catalysts.

  • CEO succession and board refresh Warren Stone, current President and COO, will become CEO in January 2027, with current CEO Tony Zook moving to Executive Chair. The planned transition and board expansion aim to support the next phase of growth, which investors took as a positive signal.

    Leadership change is a new event that can affect investor confidence and future strategy.

Latest
▲4

NeoGenomics rides new FDA test, raised guidance, and CEO transition

  • FDA-approved prostate cancer test launch NeoGenomics launched PTEN IHC CDx, the first FDA-approved lab test to identify prostate cancer patients eligible for AstraZeneca's targeted therapy TRUQAP. This new product expands its oncology menu and could drive future testing demand, pushing the stock up 3.4% on the news.

    New product launch is a fresh growth driver that directly boosts revenue potential.

  • Raised 2026 revenue and profit guidance After strong Q2 results, NeoGenomics raised its full-year 2026 revenue outlook to $802–$806 million and lifted adjusted EBITDA guidance to $56–$58 million. Clinical revenue grew 14%, led by a 26% jump in next-generation sequencing, showing the core business is accelerating.

    Guidance raise signals stronger-than-expected business momentum, a key positive for the stock.

  • Preliminary Q3 revenue beats consensus NeoGenomics reported preliminary third-quarter revenue of about $209 million, topping the $205.9 million consensus estimate, with very strong next-generation sequencing growth. The company also plans to raise its full-year guidance, reinforcing confidence in its growth trajectory.

    Better-than-expected quarterly revenue and a guidance hike are fresh positive catalysts.

  • CEO succession and board refresh Warren Stone, current President and COO, will become CEO in January 2027, with current CEO Tony Zook moving to Executive Chair. The planned transition and board expansion aim to support the next phase of growth, which investors took as a positive signal.

    Leadership change is a new event that can affect investor confidence and future strategy.